QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (38) Citing Articles via Google Scholar Google Scholar Articles by Wallace, V. C. J. Articles by Fleetwood-Walker, S. M. Search for Related Content PubMed PubMed Citation Articles by Wallace, V. C. J. Articles by Fleetwood-Walker, S. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

 Previous Article  |  Next Article 

The Journal of Neuroscience, April 15, 2003, 23(8):3221

Focal Lysolecithin-Induced Demyelination of Peripheral Afferents Results in Neuropathic Pain Behavior That Is Attenuated by Cannabinoids

Victoria C. J. Wallace, David F. Cottrell, Peter J. Brophy, and Susan M. Fleetwood-Walker

Centre for Neuroscience Research, Division of Preclinical Veterinary Sciences, The Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Summerhall, Edinburgh EH9 1QH, United Kingdom

Demyelinating diseases can be associated with painful sensory phenomena such as tactile allodynia and hyperalgesia. To study the mechanisms underlying demyelination-induced pain, we have characterized a novel model of demyelination of the sciatic or saphenous nerve. Topical lysolecithin application causes focal demyelination of afferent nerve A-fibers without axonal loss, as assessed either by electron and light microscopy or by immunohistochemical analysis of dorsal root ganglia (DRG) for a neuronal injury marker, activating transcription factor 3. Focal demyelination is accompanied by spontaneous action potentials in afferents and increased expression of neuropeptide Y and Na_v1.3 sodium channels specifically in DRG neurons that coexpress a specific marker of myelinated afferents. In contrast, expression of tetrodotoxin-resistant, Na_v1.8 sodium channels is specifically decreased in the same subgroup of DRG cells. Central sensitization of somatosensory processing is also induced, with increased behavioral reflex responsiveness to thermal and mechanical stimuli. These changes are reversed by intrathecal administration of an NMDA receptor antagonist or cannabinoid (CB) receptor agonist, but not by a µ-opioid receptor agonist. Recovery of behavioral reflexes occurred ~3 weeks after lysolecithin treatment. This is the first time that demyelination of afferent A-fibers has been shown to specifically induce neuropathic pain and indicates that axonal damage is not a prerequisite for development of the pain state. The profile of phenotypic changes in DRG is distinct from other pain models and displays a sensitivity to NMDA and CB receptor agents that may be exploitable therapeutically.

Key words: afferents; demyelination; neuropathic pain; cannabinoids; sodium channels; DRG

---

Copyright © 2003 Society for Neuroscience  0270-6474/03/2383221-13$05.00/0

This article has been cited by other articles:

				H. Jung, S. Bhangoo, G. Banisadr, C. Freitag, D. Ren, F. A. White, and R. J. Miller Visualization of Chemokine Receptor Activation in Transgenic Mice Reveals Peripheral Activation of CCR2 Receptors in States of Neuropathic Pain J. Neurosci., June 24, 2009; 29(25): 8051 - 8062. [Abstract] [Full Text] [PDF]

				A. Schmidtko, W. Gao, M. Sausbier, I. Rauhmeier, U. Sausbier, E. Niederberger, K. Scholich, A. Huber, W. Neuhuber, H.-D. Allescher, et al. Cysteine-Rich Protein 2, a Novel Downstream Effector of cGMP/cGMP-Dependent Protein Kinase I-Mediated Persistent Inflammatory Pain J. Neurosci., February 6, 2008; 28(6): 1320 - 1330. [Abstract] [Full Text] [PDF]

				F. A. White, H. Jung, and R. J. Miller Chemokines and the pathophysiology of neuropathic pain PNAS, December 18, 2007; 104(51): 20151 - 20158. [Abstract] [Full Text] [PDF]

				V. C. J. Wallace, J. Blackbeard, A. R. Segerdahl, F. Hasnie, T. Pheby, S. B. McMahon, and A. S. C. Rice Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain Brain, October 1, 2007; 130(10): 2688 - 2702. [Abstract] [Full Text] [PDF]

				F. S. Hasnie, V. C. J. Wallace, K. Hefner, A. Holmes, and A. S. C. Rice Mechanical and cold hypersensitivity in nerve-injured C57BL/6J mice is not associated with fear-avoidance- and depression-related behaviour Br. J. Anaesth., June 1, 2007; 98(6): 816 - 822. [Abstract] [Full Text] [PDF]

				C. Liu and J. M. Walker Effects of a Cannabinoid Agonist on Spinal Nociceptive Neurons in a Rodent Model of Neuropathic Pain J Neurophysiol, December 1, 2006; 96(6): 2984 - 2994. [Abstract] [Full Text] [PDF]

				R.-R. Ji and G. Strichartz Cell Signaling and the Genesis of Neuropathic Pain Sci. Signal., September 28, 2004; 2004(252): re14 - re14. [Abstract] [Full Text] [PDF]

				N. Ninkina, K. Papachroni, D. C. Robertson, O. Schmidt, L. Delaney, F. O'Neill, F. Court, A. Rosenthal, S. M. Fleetwood-Walker, A. M. Davies, et al. Neurons Expressing the Highest Levels of {gamma}-Synuclein Are Unaffected by Targeted Inactivation of the Gene Mol. Cell. Biol., November 15, 2003; 23(22): 8233 - 8245. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help